|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-8-12
|
|
pubmed:abstractText |
Ten-year follow-up results from the Parkinson's Disease Research Group of the United Kingdom trial demonstrated that there were no long-term advantages to initiating treatment with bromocriptine compared with l-dopa in early Parkinson disease (PD). Increased mortality in patients on selegiline combined with l-dopa led to premature termination of this arm after 6 years.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1526-632X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
12
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
474-80
|
|
pubmed:dateRevised |
2009-3-3
|
|
pubmed:meshHeading |
pubmed-meshheading:18579806-Antiparkinson Agents,
pubmed-meshheading:18579806-Bromocriptine,
pubmed-meshheading:18579806-Disability Evaluation,
pubmed-meshheading:18579806-Female,
pubmed-meshheading:18579806-Follow-Up Studies,
pubmed-meshheading:18579806-Humans,
pubmed-meshheading:18579806-Levodopa,
pubmed-meshheading:18579806-Male,
pubmed-meshheading:18579806-Middle Aged,
pubmed-meshheading:18579806-Motor Skills,
pubmed-meshheading:18579806-Parkinson Disease,
pubmed-meshheading:18579806-Quality of Life,
pubmed-meshheading:18579806-Selegiline
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
|
|
pubmed:affiliation |
National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
